Trial · NCT02060721
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Macitentan 10 Milligrams (mg) | 72 | Participants | ||
| Number of Participants With AEs Leading to Study Drug Discontinuation | Macitentan 10 Milligrams (mg) | 9 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) | Macitentan 10 Milligrams (mg) | 44 | Participants | ||
| Number of Participants With Hemoglobin Abnormalities | Macitentan 10 Milligrams (mg) | Hemoglobin < 80 g/L | 0 | Participants | |
| Number of Participants With Hemoglobin Abnormalities | Macitentan 10 Milligrams (mg) | Hemoglobin <100 g/L | 7 | Participants | |
| Number of Participants With Hemoglobin Abnormalities | Macitentan 10 Milligrams (mg) | Hemoglobin >= 80 g/L and <100 g/L | 7 | Participants | |
| Number of Participants With Hemoglobin Abnormalities | Macitentan 10 Milligrams (mg) | Hemoglobin <100g/L and a decrease of >20 g/L from baseline | 6 | Participants | |
| Number of Participants With Hemoglobin Abnormalities | Macitentan 10 Milligrams (mg) | Decrease of >20 g/L in hemoglobin from baseline | 32 | Participants | |
| Number of Participants With Hemoglobin Abnormalities | Macitentan 10 Milligrams (mg) | Decrease of >20 g/L and <=50 g/L in hemoglobin from baseline | 31 | Participants | |
| Number of Participants With Hemoglobin Abnormalities | Macitentan 10 Milligrams (mg) | Decrease of >50 g/L in hemoglobin from baseline | 5 | Participants | |
| Number of Participants With Liver Tests Abnormalities | Macitentan 10 Milligrams (mg) | ALT or AST >=3 x ULN | 2 | Participants | |
| Number of Participants With Liver Tests Abnormalities | Macitentan 10 Milligrams (mg) | ALT or AST >=3 and <5 x ULN | 1 | Participants | |
| Number of Participants With Liver Tests Abnormalities | Macitentan 10 Milligrams (mg) | ALT or AST >=5 x ULN | 1 | Participants | |
| Number of Participants With Liver Tests Abnormalities | Macitentan 10 Milligrams (mg) | ALT or AST >=5 and <8 x ULN | 0 | Participants | |
| Number of Participants With Liver Tests Abnormalities | Macitentan 10 Milligrams (mg) | ALT or AST >=8 x ULN | 1 | Participants | |
| Number of Participants With Liver Tests Abnormalities | Macitentan 10 Milligrams (mg) | Total Bilirubin >=2 x ULN | 8 | Participants | |
| Change From Baseline in Blood Pressure at Month 6 | Macitentan 10 Milligrams (mg) | SBP | -0.4 | Standard Deviation 13.15 | Millimeters of mercury (mmHg) |
| Change From Baseline in Blood Pressure at Month 6 | Macitentan 10 Milligrams (mg) | DBP | -2.8 | Standard Deviation 9.51 | Millimeters of mercury (mmHg) |
| Change From Baseline in Pulse Rate at Month 6 | Macitentan 10 Milligrams (mg) | -1.1 | Standard Deviation 8.76 | Beats per minute | |
| Change From Baseline in Body Weight at Month 6 | Macitentan 10 Milligrams (mg) | -0.35 | Standard Deviation 2.871 | kilograms (kg) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02060721/results